Search Videos by Topic or Participant
Browse by Series:

Final Thoughts on Improving Outcomes in CRC

Panelists: Axel F. Grothey, MD , Mayo Clinic ; Daniel G. Haller, MD, University of Pennsylvania; Herbert I. Hurwitz, MD, Duke University Medical Center; J
Published: Sunday, Jun 07, 2015


In the final segment of the discussion, the expert panel shares their thoughts on the current state of treatment for patients with metastatic colorectal cancer (mCRC).

Dan Haller, MD, explains that overall survival for mCRC has improved 5-fold since he trained as a fellow, back when there was only fluorouracil; in fact, some patients with metastatic disease are now being cured. It’s important to realize how far we’ve come, he comments.

Axel Grothey, MD, says there is no clear winner when it comes to choosing first-line therapy for mCRC. There are several options, and it’s not a one-size-fits-all scenario. The next generation of big questions will be answered by diving into the subset analyses of large phase III studies, he suggests.
Slider Left
Slider Right


In the final segment of the discussion, the expert panel shares their thoughts on the current state of treatment for patients with metastatic colorectal cancer (mCRC).

Dan Haller, MD, explains that overall survival for mCRC has improved 5-fold since he trained as a fellow, back when there was only fluorouracil; in fact, some patients with metastatic disease are now being cured. It’s important to realize how far we’ve come, he comments.

Axel Grothey, MD, says there is no clear winner when it comes to choosing first-line therapy for mCRC. There are several options, and it’s not a one-size-fits-all scenario. The next generation of big questions will be answered by diving into the subset analyses of large phase III studies, he suggests.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x